Feasibility and Functionality of fPAM Imaging in Melanoma (fPAM)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00776945
: October 22, 2008
Last Update Posted
: June 8, 2015
Washington University School of Medicine
Information provided by (Responsible Party):
Lynn Cornelius, MD, Washington University School of Medicine
Melanoma is a cutaneous malignancy that has the potential for local (skin) and regional (lymph node) recurrence. These recurrences may be difficult to detect in their earliest stages. We are attempting to use novel form of skin imaging that uses ultrasound combined with laser to identify these recurrences early, when they may be most amenable to treatment. This imaging will detect melanoma pigment below the surface of the skin and in the draining lymph nodes, as well as new blood vessel formation that occurs with these loco-regional metastases.
Condition or disease
recruiting healthy individuals with pigmented lesions and individuals with melanoma and pigmented lesions
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients with Stage I - III melanoma.
Adult patients (> 18 yrs of age) with recently diagnosed or a history of, Stage I - III melanoma who are able to give informed consent.
Patients with melanomas < 1mm.
Children and young adults < 18 yrs of age and patients who are unable to give informed consent.